Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders

NCT01273064 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

114

Enrollment

INDUSTRY

Sponsor class

Stopped Risk-benefit ratio

Conditions

Hepatitis C

Interventions

DRUG: CTS-1027
DRUG: pegylated interferon
DRUG: Ribavirin
DRUG: Placebo

Sponsor

Conatus Pharmaceuticals Inc.